BIOMM SA engages in the research, development, and manufacture of insulin. Its technology is suitable for the production of therapeutic proteins such as calcitonin, interferons and growth hormones. The company was founded on September 19, 2001 and is headquartered in Belo Horizonte, Brazil.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company